|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Incomplete revascularization reduces survival benefit of coronary artery bypass grafting: role of off- pump surgery显示文摘 | Synnergren M J Ekroth R Odin A | 2008 | J Thorac Cardiovasc Surg2008，136，1： | 1 |
| 2 | In vitro effects of Choukroun's PRF(platelet-rich fibrin)on human gingival fibroblasts,dermal prekeratinocytes,preadipocytes,and maxillofacial osteoblasts in primary cultures显示文摘 | DOHAN EHRENFEST D M DISS A ODIN G | 2009 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod2009，108，3： | 1 |
| 3 | Computer aided analysis of digitized dental stone replicas by dental CAD/CAM technology显示文摘 | Persson AS Andersson M Odin A | 2008 | Dent Mater2008，24，8： | 1 |
| 4 | In vitroeffects of Ghoukroun's PRF ( platelet - rich fibrin) on human gin-gival fibroblasts,dermal prekeratinocytes,preadipocytes,andmaxillofacial osteoblasts in primary cultures 显示文摘 | DOHAN EHRENFEST D M DISS A ODIN G | 2009 | Oral Surg OralMed Oral Pathol Oral Radiol Endod2009，108，3： | 1 |
| 5 | Physic-chemical tool in Jurassic stratigraphy显示文摘 | Galbrum B Renard M | 1992 | Bulletin of Liason and Information of IUGS Subcom mission on Geochronology1992，10，： | 1 |
| 6 | Microstructure, stress and mechanical properties of arc-evaporated Cr-C-N coatings 显示文摘 | Almer J Odin M Hfikansson G | 2001 | Thin Solid Films2001，385，12： | 1 |
| 7 | Postulated carbon tetrachloride mode of action: a review显示文摘 | Manibusan MK Odin M Eastmond DA | 2007 | J Environ Sci Health C Environ Carcinog Ecotoxicol Rev2007，25，： | 1 |
| 8 | Biocompatibility evaluation of dura mater substitutes in an animal model 显示文摘 | Barbolt TA Odin M Leqer M | 2001 | Neurol Res2001，23，8： | 1 |
| 9 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 10 | Mesoscale predictability of an extreme warm-season precipitation event 显示文摘 | Zhang F Q Odins A M Nielsen-Gammon J W | 2006 | Weather and Forecasting2006，21，2： | 1 |
| 11 | In vitro elects of Choukroun's PRF (platelet-rich fibrin) on human gingivalfibro- blasts, dermal prekeratinocytes, preadipocytes, and maxillofacial osteoblasts in primary cultures 显示文摘 | Dohan Ehrenfest D M Diss A Odin G | 2009 | Oral Surg Oral Med Oral PatholOralRadiolEndod2009，108，3： | 1 |
| 12 | L aparoscopic cholecy stectomy in acute cholecy stitis:a proposalofsafe and effective technique显示文摘 | CataniM M odiniC | 2007 | H epatogastroenterology2007，54，80： | 1 |
| 13 | Biocompatibility evaluation of dura mater substitutes in an animal model显示文摘 | Barbolt TA Odin M Leger M | 2001 | Neurol Res2001，23，8： | 1 |
| 14 | Nielsen-Gammon: Mesoscale predictability of an extreme warm-sea- son precipitation event显示文摘 | Zhang Fuqing Andrew M Odins John W | 2006 | Weather and Forecasting2006，21，： | 1 |
| 15 | Peripheral neuropathy in Parkinson’s disease: Levodopa exposure and implications for duodenal delivery显示文摘 | Thomas Müller Teus van Laar David R. Cornblath Per Odin Fabian Klostermann Francisco J. Grandas Georg Ebersbach Peter P. Urban Francesc Valldeoriola Angelo Antonini | 2013 | Parkinsonism and Related Disorders2013，，： | 1 |
| 16 | Extreme rainfall in Texas: patterns and predictability显示文摘 | Nielsen-Gammon J W Zhang F Odins A M | 2005 | Physical Geography2005，26，5： | 1 |
| 17 | Current state of stem cell research for the treatment of Parkinson's diseases 显示文摘 | Braak H Hartmann A Jost WH Odin P Priller J Schwarz J | 2002 | J Neurol2002，249，3： | 1 |
| 18 | Biocompatibility evaluation of dura mater substitutes in an animal model 显示文摘 | Barboh TA Odin M Leger M | 2001 | Neurol Res2001，23，8： | 1 |
| 19 | Factors associated with success of telaprevir-and boceprevir-based triple therapy for hepatitis C virus infection显示文摘AIM To evaluate new therapies for hepatitis C virus(HCV), data about real-world outcomes are needed.METHODS Outcomes of 223 patients with genotype 1 HCV who started telaprevir-or boceprevir-based triple therapy(May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunodeficiency viruspositive patients and patients who received a liver transplant were excluded. Factors associated with sustained virological response(SVR24) and relapse were analyzed by univariable and multivariable logistic regression as well as classification and regression trees. Fast virological response(FVR) was defined as undetectable HCV RNA at week-4(telaprevir) or week-8(boceprevir). RESULTS The median age was 57 years, 18% were black, 44% had advanced fibrosis/cirrhosis(FIB-4 ≥ 3.25). Only 42%(94/223) of patients achieved SVR24 on an intention-totreat basis. In a model that included platelets, SVR24 was associated with white race [odds ratio(OR) = 5.92, 95% confidence interval(CI): 2.34-14.96], HCV sub-genotype 1b(OR = 2.81, 95%CI: 1.45-5.44), platelet count(OR = 1.10, per x 104 cells/μL, 95%CI: 1.05-1.16), and IL28 B CC genotype(OR = 3.54, 95%CI: 1.19-10.53). Platelet counts > 135 x 103/μL were the strongest predictor of SVR by classification and regression tree. Relapse occurred in 25%(27/104) of patients with an end-oftreatment response and was associated with non-FVR(OR = 4.77, 95%CI: 1.68-13.56), HCV sub-genotype 1a(OR = 5.20; 95%CI: 1.40-18.97), and FIB-4 ≥ 3.25(OR = 2.77; 95%CI: 1.07-7.22). CONCLUSION The SVR rate was 42% with telaprevir-or boceprevirbased triple therapy in real-world practice. Low platelets and advanced fibrosis were associated with treatment failure and relapse. | Kian Bichoupan Neeta Tandon Valerie Martel-Laferriere Neal M Patel David Sachs Michel Ng Emily A Schonfeld Alexis Pappas James Crismale Alicia Stivala Viktoriya Khaitova Donald Gardenier Michael Linderman William Olson Ponni V Perumalswami Thomas D Schiano Joseph A Odin Lawrence U Liu Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Hepatology2017，9，11： | 0 |
| 20 | Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus显示文摘AIM: To describe our experience using a low-acceleratingdose regimen(LADR) with pegylated interferon alpha-2a and ribavirin in treatment of hepatitis C virus(HCV) recurrence. METHODS: From 2003, a protocolized LADR strategy was employed to treat liver transplant(LT) recipients with recurrent HCV at our institution. Medical records of 182 adult patients with recurrent HCV treated with LADR between 1/2003 and 1/2011 were reviewed. Histopathology from all post-LT liver biopsies were reviewed in a blinded fashion. Paired recipient and donor IL28 B status were assessed. A novel technique was employed to ascertain recipient and donor IL28B(rs12979860) Gt data using DNA extracted from archival FFPE tissue from explanted native livers and donor gallbladders respectively. The primary endpoint was SVR; secondary endpoints examined include(1) patient and graft survival;(2) effect of anti-viral therapy on liver histology(fibrosis and inflammation);(3) incidence of on-treatment development of ACR, CDR, or PCH;(4) association of recipient and donor IL28 B genotype with SVR; and(5) incidence of antiviral therapy-associated adverse events(anemia, leukopenia, thrombocytopenia, depression) and hepatic decompensation.RESULTS: The overall SVR rate was 38%(29% Gt1, 67% Gt2, 86% Gt3 and 58% Gt4). HCV Gt(P < 0.0001), donor age(P = 0.003), cytomegalovirus mismatch(P = 0.001), baseline serum bilirubin(P = 0.002), and baseline viral load(P = 0.04) were independent predictors for SVR. SVR rates were significantly higher in the recipient-CC/donor-non CC pairs(P = 0.007). Neither baseline fibrosis nor change in fibrosis stage after anti-viral therapy were associated with SVR. Fibrosis progressed in 72% of patients despite SVR. Median graft survival was 91 mo. Five-year patient survival was superior in patients who achieved SVR(97% vs 82%, P = 0.001). Pre-treatment ALP ≥ 150 U/L(P = 0.01), total bilirubin ≥ 1.5 mg/d L(P = 0.001) and creatinine ≥ 2 mg/d L(P = 0.001) were independently associated with patient survival. Only 13% of patients achieving SVR died during the followup period. Treatment discontinuation and treatmentrelated mortality occurred in 35% and 2.2% of patients, respectively. EPO, G-CSF and blood transfusion were needed in 89%, 40% and 23% of patients, respectively. Overall hospitalization rate for treatment-related serious adverse events was 21%. Forty-six(25%) of the patients were deceased; among those who died, 25(54%) were due to liver-related complications, and 4 deaths(9%) occurred while receiving therapy(2 patients experienced hepatic decompensation and 2 sepsis). CONCLUSION: LADR strategy remains relevant in managing post-LT recurrent HCV where access to DAAs is limited. SVR is associated with improved survival, but fibrosis progression still occurs. | Kieron BL Lim Hamid R Sima M Isabel Fiel Viktoriya Khaitova John T Doucette Maria Chernyiak Jawad Ahmad Nancy Bach Charissa Chang Priya Grewal Leona Kim-Schluger Lawrence Liu Joseph Odin Ponni Perumalswami Sander S Florman Thomas D Schiano | 2015 | World Journal of Gastroenterology2015，21，20： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员